LABU

Leveraged & Inverse Channel

Big Biopharma Mergers Could Fuel These ETFs in 2019

By Ben HernandezJanuary 10, 2019

Leveraged & Inverse Channel

Biotech ETFs Hoping This Post-Election Trend Doesn’t Repeat

By Brenton GarenNovember 8, 2018

Leveraged & Inverse Channel

After a Rough October, Leveraged Biotech ETF Looks to Bounce Back

By Brenton GarenNovember 6, 2018

Equity ETFs

Pharma, Biotech Bull ETFs Leading the Charge

By Ben HernandezJuly 12, 2018

Leveraged & Inverse Channel

5 Big Direxion ETFs Trending This Week

By Ben HernandezJune 22, 2018

Equity ETFs

Big Biotech ETF Can Bounce Back

By Tom LydonApril 18, 2018

Equity ETFs

Catalysts Abound for Biotech ETFs

By Tom LydonApril 10, 2018

Equity ETFs

Betting Big on Biotech ETFs? Traders Leverage ETFs

By Brenton GarenMarch 28, 2018

Equity ETFs

Good Reasons to Stick With Biotech ETFs

By Tom LydonMarch 12, 2018

Equity ETFs

Healthcare Dip Could be a Buying Opportunity

By Brenton GarenFebruary 5, 2018

Equity ETFs

Biotech ETFs Pop on Celgene, Juno Deal

By Max ChenJanuary 22, 2018

Equity ETFs

Adding Some Juice to the Healthcare Trade

By Tom LydonJanuary 10, 2018

Equity ETFs

Biotech Slump Could be a Buying Opportunity

By Tom LydonDecember 5, 2017

Equity ETFs

Biotech Decline Could be a Buying Opportunity

By Brenton GarenNovember 16, 2017

Equity ETFs

Bullish Biotech Bets After Positive Attention

By Tom LydonOctober 5, 2017

Equity ETFs

A Good Time to Own Biotech ETFs

By Tom LydonOctober 2, 2017

Equity ETFs

Evaluating the Biotech ETF Rally

By Tom LydonSeptember 28, 2017

Equity ETFs

Biotech, Pharma ETFs Leave Pricing Drama Behind

By Max ChenSeptember 15, 2017